DexCom, Inc. (NASDAQ:DXCM) EVP Sells $124,697.96 in Stock

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Sadie Stern sold 1,466 shares of the stock in a transaction that occurred on Thursday, June 26th. The shares were sold at an average price of $85.06, for a total transaction of $124,697.96. Following the transaction, the executive vice president owned 108,155 shares in the company, valued at approximately $9,199,664.30. This trade represents a 1.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Sadie Stern also recently made the following trade(s):

• On Tuesday, May 27th, Sadie Stern sold 6,184 shares of DexCom stock. The shares were sold at an average price of $85.11, for a total transaction of $526,320.24.

DexCom Price Performance

NASDAQ:DXCM traded down $3.71 on Tuesday, reaching $83.58. 5,587,879 shares of the company's stock traded hands, compared to its average volume of 4,394,654. The stock has a 50-day simple moving average of $82.47 and a 200-day simple moving average of $79.69. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $117.19. The firm has a market cap of $32.77 billion, a PE ratio of 62.37, a P/E/G ratio of 1.86 and a beta of 1.44. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.55.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The business had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same quarter in the prior year, the business posted $0.32 EPS. The business's revenue for the quarter was up 12.5% compared to the same quarter last year. Equities research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on DXCM. Piper Sandler dropped their price target on DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. The Goldman Sachs Group initiated coverage on DexCom in a research report on Friday, May 30th. They issued a "buy" rating and a $104.00 target price on the stock. Barclays boosted their price target on DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a research note on Monday, May 5th. Truist Financial initiated coverage on shares of DexCom in a research note on Monday, June 16th. They issued a "buy" rating and a $102.00 price objective on the stock. Finally, Cfra Research raised shares of DexCom to a "hold" rating in a report on Friday, March 21st. Five research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $98.50.

Institutional Investors Weigh In On DexCom

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in DexCom by 2.0% during the first quarter. Vanguard Group Inc. now owns 47,455,899 shares of the medical device company's stock valued at $3,240,763,000 after acquiring an additional 925,882 shares in the last quarter. Jennison Associates LLC lifted its stake in DexCom by 37.7% in the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company's stock worth $718,632,000 after purchasing an additional 2,879,489 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of DexCom by 22.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company's stock valued at $691,336,000 after purchasing an additional 1,868,241 shares during the last quarter. Geode Capital Management LLC grew its position in shares of DexCom by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock valued at $775,256,000 after purchasing an additional 56,094 shares in the last quarter. Finally, Nuveen LLC bought a new stake in shares of DexCom in the first quarter worth about $554,893,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.